Synthace
PrivateLast Round
Series C
Nov 16, 2021
Est. Valuation
$71.3M
Total Funding Raised
$76.37M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Synthace operates in Healthcare & Life Sciences and is based in London, England. Its latest recorded funding round was a Series C round in November 2021.
Synthace is a biotechnology company that offers a laboratory automation platform aimed at transforming biological experimentation by streamlining data management and facilitating the planning and execution of complex experiments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Vertical SaaS, Workflow Automation
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Synthace Comparables
Compare Synthace with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Labforward | 82% | |
| TetraScience | 80% | |
| Artificial, Inc. | 80% |
For institutional investors. Book with your work email.
Synthace Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 16, 2021 | ||||
| Series B | Dec 12, 2018 | ||||
| Series A | Sep 19, 2017 | ||||
| Seed | Feb 11, 2015 | ||||
| Seed | Sep 23, 2014 | ||||
Grant | Mar 7, 2013 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Synthace Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Amadeus Capital Partners | Series A |
| Horizons Ventures | Series B, Series C |
| Voyagers.io | Series C |
| Biotechnology and Biological Sciences Research Council (BBSRC) | Grant |
| Innovate UK | Grant |
| UK Innovation & Science Seed Fund | Seed |
| Bioeconomy Capital | Seed, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 32% MoM.
- Apr 1, 2026
Added Charles River Laboratories International as a customer.
For institutional investors. Book with your work email.
Synthace Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Synthace's valuation, stock price, and market status.
Is Synthace a public or private company?
Synthace is a private company.
What is the current stock price of Synthace?
Synthace is a private company, so its shares have no public market price. Caplight tracks Synthace's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Synthace worth (valuation)?
Synthace's valuation is estimated at $71.3M based on funding round data.
Can I buy Synthace stock?
Synthace shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Synthace's last funding round?
Synthace's most recent funding round was Series C on November 16, 2021.
Who are the main investors in Synthace?
Key investors in Synthace include Horizons Ventures, Sofinnova Partners, 11.2 Capital.
Will Synthace IPO soon?
No public IPO plans have been announced for Synthace.
How can I track Synthace secondary market activity?
Caplight tracks bids, offers, and trades in Synthace's shares on secondary markets.